Actively Recruiting

Age: 18Years +
All Genders
NCT05891379

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Led by Xuanwu Hospital, Beijing · Updated on 2024-09-19

50

Participants Needed

1

Research Sites

55 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.

CONDITIONS

Official Title

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older with anti-AQP4-IgG seropositive NMOSD as defined by 2015 diagnostic criteria by IPND
  • Currently in the acute phase of NMOSD, with new or worsening neurological symptoms within 30 days before screening lasting at least 24 hours without fever
  • Planning to receive or currently receiving intravenous methylprednisolone therapy
  • Expanded Disability Status Scale (EDSS) score between 2.5 and 8 during screening
  • Able and willing to give written informed consent
  • Women of childbearing potential agree to use adequate contraception during the study
Not Eligible

You will not qualify if you...

  • Pregnant or lactating females
  • Participation in other interventional studies within 30 days before screening or within 5 half-lives of the investigational agent before enrollment
  • Severe mental disorders or other conditions preventing cooperation with follow-up
  • History of malignancies
  • Received plasma exchange, immunoadsorption, or intravenous immunoglobulin therapy within 1 month before screening
  • Negative hepatitis B surface antigen and positive hepatitis B core antibody, or positive hepatitis B surface antigen carriers, or active tuberculosis or positive tuberculosis screening without appropriate treatment
  • Other conditions judged by researchers as unsuitable for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100053

Actively Recruiting

Loading map...

Research Team

J

Junwei Hao, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders | DecenTrialz